

# Long-term survival in ovarian cancer

European Journal of Cancer & Clinical Oncology  
27, 1367-1372

DOI: [10.1016/0277-5379\(91\)90011-2](https://doi.org/10.1016/0277-5379(91)90011-2)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Treatment of advanced ovarian cancer: 10 years of experience. <i>Annals of Oncology</i> , 1992, 3, 17-27.	0.6	19
2	Sequential cisplatin - doxorubicin, early debulking in advanced ovarian cancer. <i>European Journal of Cancer</i> , 1992, 28, 1009-1010.	1.3	0
3	Hexamethylmelamine in platinum-resistant ovarian cancer: How active?. <i>Gynecologic Oncology</i> , 1992, 47, 279-281.	0.6	9
4	Primary treatment of epithelial ovarian malignancies. <i>Cancer</i> , 1993, 71, 1541-1550.	2.0	17
5	Secondâ€line chemotherapy for recurrent carcinoma of the ovary. <i>Cancer</i> , 1993, 71, 1559-1564.	2.0	110
6	New platinum antitumor complexes. <i>Critical Reviews in Oncology/Hematology</i> , 1993, 15, 191-219.	2.0	199
7	The role of platinum dose intensity in the management of ovarian cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 1993, 119, 511-512.	1.2	2
9	The prognostic value of epidermal growth factor receptors, determined by both immunohistochemistry and ligand binding assays, in primary epithelial ovarian cancer: a pilot study. <i>European Journal of Cancer</i> , 1993, 29, 1951-1957.	1.3	36
10	Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. <i>Cancer Treatment Reviews</i> , 1993, 19, 79-86.	3.4	30
11	Chemotherapy for ovarian cancer. <i>European Journal of Cancer</i> , 1993, 29, 632-635.	1.3	6
12	What have we learnt from meta-analyses in ovarian cancer?. <i>Annals of Oncology</i> , 1993, 4, S79-S82.	0.6	2
13	Long-term follow-up of patients with advanced ovarian carcinoma treated with chemotherapy. <i>Annals of Oncology</i> , 1993, 4, S35-S40.	0.6	22
14	Carboplatin versus cisplatin. <i>Annals of Oncology</i> , 1993, 4, S41-S48.	0.6	61
15	The management of ovarian cancer. <i>Annals of Oncology</i> , 1993, 4, 883-887.	0.6	0
16	Cancer of the Ovary. <i>New England Journal of Medicine</i> , 1994, 330, 1012-1014.	13.9	0
17	Primary chemotherapy of epithelial ovarian carcinoma. <i>Journal of Surgical Oncology</i> , 1994, 10, 283-289.	1.4	2
18	Long term survival by cytoreductive surgery to less than 1 cm, induction weekly cisplatin and monthly cisplatin, doxorubicin, and cyclophosphamide therapy in advanced ovarian adenocarcinoma. <i>Cancer</i> , 1994, 74, 656-663.	2.0	43
20	Platinum anticancer drugs. , 1994, , 32-45.		4

#	ARTICLE	IF	CITATIONS
21	Modern chemotherapy for gynaecological cancer. Part 2: drugs and diseases – the view from the clinic. <i>Current Obstetrics &amp; Gynaecology</i> , 1994, 4, 23-31.	0.2	0
22	A randomised study of cisplatin versus thiotepa as induction chemotherapy in advanced ovarian carcinoma. <i>European Journal of Cancer</i> , 1994, 30, 1470-1474.	1.3	4
23	Second-line chemotherapy in epithelial ovarian carcinoma: Platinum again? Taxanes? How to choose?. <i>European Journal of Cancer</i> , 1994, 30, 1739-1741.	1.3	3
24	New Platinum Agents. <i>Drugs and Aging</i> , 1994, 5, 85-95.	1.3	16
25	Phase II trial of intraperitoneal carboplatin in ovarian carcinoma patients with macroscopic residual disease at second-look laparotomy. <i>Annals of Oncology</i> , 1994, 5, 127-132.	0.6	19
26	Mechanism of action of an orally administered platinum complex [amine bis butyrato cyclohexylamine dichloroplatinum (IV) (JM221)] in intrinsically cisplatin-resistant human ovarian carcinoma in vitro. <i>British Journal of Cancer</i> , 1994, 69, 1-7.	2.9	19
27	Long-term follow-up of patients with advanced ovarian cancer treated in randomised clinical trials. <i>British Journal of Cancer</i> , 1995, 72, 1513-1517.	2.9	53
28	The treatment of epithelial ovarian cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 1995, 45, 88-101.	157.7	42
29	Treatment of advanced epithelial ovarian cancer: past, present and future. <i>Critical Reviews in Oncology/Hematology</i> , 1995, 20, 41-59.	2.0	6
30	What have we achieved in ovarian cancer? A comparison of survivals and resources in two different periods. <i>International Journal of Gynecological Cancer</i> , 1995, 5, 148-155.	1.2	4
31	Carboplatin and etoposide as first-line chemotherapy in advanced epithelial ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 1995, 5, 443-448.	1.2	6
32	Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. <i>Journal of Clinical Oncology</i> , 1995, 13, 1589-1599.	0.8	215
33	Optimal Chemotherapy of Ovarian Cancer with an Old Regimen. <i>Annals of Medicine</i> , 1995, 27, 121-125.	1.5	2
34	Long-term prognosis following macroscopic complete response at second-look laparotomy in advanced ovarian cancer patients treated with platinum-based chemotherapy. <i>European Journal of Cancer</i> , 1995, 31, 296-301.	1.3	19
35	An evaluation of prognostic factors in advanced ovarian cancer. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 1995, 63, 115-124.	0.5	8
36	Second-look laparotomy for stage III epithelial ovarian cancer: rationale and current issues. <i>Cancer Treatment Reviews</i> , 1995, 21, 499-511.	3.4	20
37	Australasian multicentre phase II study of paclitaxel (Taxol*) in relapsed ovarian cancer. <i>Australian and New Zealand Journal of Medicine</i> , 1995, 25, 337-343.	0.5	10
38	The Effect of Debulking Surgery after Induction Chemotherapy on the Prognosis in Advanced Epithelial Ovarian Cancer. <i>New England Journal of Medicine</i> , 1995, 332, 629-634.	13.9	706

#	ARTICLE	IF	CITATIONS
39	Altretamine. <i>Drugs</i> , 1995, 49, 932-953.	4.9	23
40	Carboplatin alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: a hellenic co-operative oncology group study. <i>European Journal of Cancer</i> , 1996, 32, 421-428.	1.3	16
41	Ovarian cancer incidence (1989-1991) and mortality (1954-1993) in the Netherlands. <i>Obstetrics and Gynecology</i> , 1996, 88, 387-393.	1.2	23
42	Clinical trials in patients with epithelial ovarian cancer: past, present and future. <i>European Journal of Surgical Oncology</i> , 1996, 22, 455-466.	0.5	20
43	Current Drug Treatment Guidelines for Epithelial Ovarian Cancer. <i>Drugs</i> , 1996, 51, 571-584.	4.9	15
44	Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy.. <i>Journal of Clinical Oncology</i> , 1996, 14, 343-350.	0.8	154
45	Doxorubicin-Melphalan with and Without Cisplatin in Advanced Ovarian Cancer: Ten-year survival results from a prospective randomized study by the Swedish Cooperative Ovarian Cancer Study Group. <i>Acta Oncologica</i> , 1996, 35, 109-118.	0.8	8
46	Primary debulking surgery in advanced ovarian carcinoma. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1996, 103, 291-293.	1.1	5
47	Intraperitoneal photodynamic therapy of the rat CC531 adenocarcinoma. <i>British Journal of Cancer</i> , 1996, 73, 1387-1392.	2.9	24
48	The role of high dose chemotherapy in adult solid tumours other than breast cancer. <i>Annals of Oncology</i> , 1996, 7, 23-30.	0.6	4
49	High-dose Chemotherapy with Autologous Stem Cell Support in Advanced Ovarian Cancer. <i>Annals of Medicine</i> , 1996, 28, 151-158.	1.5	9
50	New Therapy for Ovarian Cancer. <i>New England Journal of Medicine</i> , 1996, 334, 50-51.	13.9	36
51	Value of quantitative pathological variables as prognostic factors in advanced ovarian carcinoma.. <i>Journal of Clinical Pathology</i> , 1996, 49, 142-148.	1.0	22
52	Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. <i>Annals of Oncology</i> , 1996, 7, 1065-1070.	0.6	116
53	Treatment of ovarian cancer with surgery, short-course chemotherapy and whole abdominal radiation. <i>Annals of Oncology</i> , 1996, 7, 65-70.	0.6	12
54	The role of second-look laparotomy in the long-term survival in ovarian cancer. <i>Annals of Oncology</i> , 1997, 8, 643-648.	0.6	18
55	Experience with intraperitoneal cisplatin and etoposide and i.v. sodium thiosulphate protection in ovarian cancer patients with either pathologically complete response or minimal residual disease. <i>Annals of Oncology</i> , 1997, 8, 1235-1241.	0.6	29
56	Activity of Anthracyclines in Refractory Ovarian Cancer: Recent Experience and Review. <i>Cancer Investigation</i> , 1997, 15, 329-334.	0.6	11

#	ARTICLE	IF	CITATIONS
57	Phase II Trial of High-Dose Cisplatin Plus Ifosfamide as First-Line Followed by Carboplatin as Second-Line Treatment in Epithelial Ovarian Carcinoma. <i>Gynecologic Oncology</i> , 1997, 66, 66-70.	0.6	4
58	Anticancer drug evaluation: Continuing progress from existing methodology. <i>European Journal of Cancer</i> , 1997, 33, S8-S10.	1.3	2
59	A phase II trial of fixed-dose carboplatin and escalating paclitaxel in advanced ovarian cancer. <i>European Journal of Cancer</i> , 1997, 33, 592-595.	1.3	14
60	Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer.. <i>Journal of Clinical Oncology</i> , 1997, 15, 2691-2700.	0.8	95
61	WART revisited: The treatment of epithelial ovarian cancer by whole abdominal radiotherapy. <i>Journal of Medical Imaging and Radiation Oncology</i> , 1997, 41, 276-280.	0.6	8
62	Single-agent paclitaxel in patients with previously untreated stage IV epithelial ovarian cancer. <i>British Journal of Cancer</i> , 1997, 75, 710-714.	2.9	8
63	The effect of sodium thiosulfate on ototoxicity and pharmacokinetics after cisplatin treatment in guinea pigs. <i>European Archives of Oto-Rhino-Laryngology</i> , 1997, 254, 281-286.	0.8	33
64	Escalating protein doses of chimeric monoclonal antibody MOv18 immunoglobulin G in ovarian carcinoma patients: A phase I study. <i>Cancer</i> , 1997, 80, 2712-2720.	2.0	36
65	Response to Salvage Treatment in Recurrent Ovarian Cancer Treated Initially with Paclitaxel and Platinum-Based Combination Regimens. <i>Gynecologic Oncology</i> , 1998, 68, 178-182.	0.6	20
66	Five-Year Survival after Second-Line Cisplatin-Based Intraperitoneal Chemotherapy for Advanced Ovarian Cancer. <i>Gynecologic Oncology</i> , 1998, 68, 267-273.	0.6	28
67	Factors Predictive of Survival after First Relapse or Progression in Advanced Epithelial Ovarian Carcinoma: A Prediction Tree Analysis-Derived Model with Test and Validation Groups. <i>Gynecologic Oncology</i> , 1998, 70, 224-230.	0.6	28
68	Hysterectomy: indications, surgical routes, cases for adnexal or cervical conservation. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 1998, 80, 5-15.	0.5	13
69	Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. <i>European Journal of Cancer</i> , 1998, 34, 148-154.	1.3	217
70	Essay: Should Cost Be Considered in the Overall Evaluation of Phase II Clinical Trials of New Antineoplastic Therapies? A Response. <i>Cancer Investigation</i> , 1998, 16, 135-139.	0.6	4
71	Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.. <i>Journal of Clinical Oncology</i> , 1998, 16, 3345-3352.	0.8	312
72	Efficacy and safety of the paclitaxel and carboplatin combination in patients with previously treated advanced ovarian carcinoma. <i>Annals of Oncology</i> , 1998, 9, 37-43.	0.6	37
73	Docetaxel and Cisplatin in Combination as First-Line Chemotherapy for Advanced Epithelial Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 1999, 17, 2069-2069.	0.8	65
74	Gynaecological cancer. <i>Postgraduate Medical Journal</i> , 1999, 75, 332-338.	0.9	5

#	ARTICLE	IF	CITATIONS
75	Blood platelets and serum VEGF in cancer patients. <i>British Journal of Cancer</i> , 1999, 79, 370-376.	2.9	52
76	Peripheral neuropathy due to biweekly paclitaxel, epirubicin and cisplatin in patients with advanced ovarian cancer. <i>Journal of Neuro-Oncology</i> , 1999, 45, 241-246.	1.4	24
77	FUTURE DIRECTIONS WITH TAXANE THERAPY. <i>Hematology/Oncology Clinics of North America</i> , 1999, 13, 21-41.	0.9	7
78	First-Line Chemotherapy in Advanced Ovarian Cancer: State of the Art and Future Aspects. <i>Oncology Research and Treatment</i> , 1999, 22, 269-280.	0.8	3
79	A Phase I Study of Paclitaxel and Epirubicin, without and with Filgrastim, for the Treatment of Platinum-Resistant Advanced Ovarian Cancer. <i>Oncology</i> , 1999, 56, 267-273.	0.9	4
80	Natural History of Stage IV Epithelial Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 1999, 17, 767-767.	0.8	101
81	Primary cytoreductive surgery with rectosigmoid colon resection for patients with advanced epithelial ovarian carcinoma. , 2000, 88, 389-397.		88
82	An analysis of ovarian tumor diameter and survival. <i>International Journal of Gynecological Cancer</i> , 2000, 10, 449-451.	1.2	7
83	Surgical versus chemical upfront debulking in advanced ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2000, 10, 12-15.	1.2	5
84	The role of intraperitoneal chemotherapy in epithelial ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2000, 10, 26-32.	1.2	16
85	Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy. <i>International Journal of Gynecological Cancer</i> , 2000, 10, 44-46.	1.2	84
86	High dose chemotherapy with peripheral blood stem cell transplantation (PBSCT) in ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2000, 10, 53-56.	1.2	11
87	Binding properties of an orally active platinum anti-tumor drug JM216 with metallothionein in vivo. <i>BioMetals</i> , 2000, 13, 203-208.	1.8	3
88	Development of a Panel of 15 Human Ovarian Cancer Xenografts for Drug Screening and Determination of the Role of the Glutathione Detoxification System. <i>Gynecologic Oncology</i> , 2000, 76, 362-368.	0.6	38
89	Effect of Topotecan on Serum CA-125 in Patients with Advanced Epithelial Ovarian Cancer. <i>Gynecologic Oncology</i> , 2000, 77, 383-388.	0.6	10
90	Docetaxel for Patients With Paclitaxel-Resistant MÅ¼lllerian Carcinoma. <i>Journal of Clinical Oncology</i> , 2000, 18, 2733-2739.	0.8	116
91	Phase II Feasibility Study of Sequential Couplets of Cisplatin/Topotecan Followed by Paclitaxel/Cisplatin as Primary Treatment for Advanced Epithelial Ovarian Cancer: A National Cancer Institute of Canada Clinical Trials Group Study. <i>Journal of Clinical Oncology</i> , 2000, 18, 4038-4044.	0.8	57
92	Oxaliplatin or Paclitaxel in Patients With Platinum-Pretreated Advanced Ovarian Cancer: A Randomized Phase II Study of the European Organization for Research and Treatment of Cancer Gynecology Group. <i>Journal of Clinical Oncology</i> , 2000, 18, 1193-1202.	0.8	146

#	ARTICLE	IF	CITATIONS
93	Ovarial cancer: best timing and applications of debulking surgery. <i>Annals of Oncology</i> , 2000, 11, 141-144.	0.6	4
94	Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot. <i>European Journal of Surgical Oncology</i> , 2000, 26, 663-668.	0.5	64
95	Drug Therapy for Gynaecological Cancer in Older Women. <i>Drugs and Aging</i> , 2000, 17, 13-32.	1.3	14
96	Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2. <i>British Journal of Cancer</i> , 2001, 85, 1359-1367.	2.9	86
97	Treatment of advanced ovarian cancer. <i>European Journal of Cancer</i> , 2001, 37, 1-7.	1.3	26
98	Clinical Evidence for Topotecan-Paclitaxel Non-Resistance in Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2001, 19, 1893-1900.	0.8	84
99	High-dose chemotherapy for ovarian carcinoma: Long-term results from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT). <i>Annals of Oncology</i> , 2001, 12, 693-699.	0.6	32
100	Phase II study of high-dose megestrol acetate in platinum-refractory epithelial ovarian cancer. <i>Anti-Cancer Drugs</i> , 2001, 12, 719-724.	0.7	30
101	Advanced ovarian cancer. <i>Current Treatment Options in Oncology</i> , 2001, 2, 109-118.	1.3	43
102	Identification of Prognostic Factors in Advanced Epithelial Ovarian Carcinoma. <i>Gynecologic Oncology</i> , 2001, 82, 532-537.	0.6	211
103	High-dose chemotherapy as a consolidation approach in advanced ovarian cancer: long-term results. <i>Bone Marrow Transplantation</i> , 2001, 27, 1017-1025.	1.3	14
104	A phase I and pharmacokinetic study of intraperitoneal topotecan. <i>British Journal of Cancer</i> , 2001, 85, 1627-1633.	2.9	27
105	A Systematic Overview of Chemotherapy Effects in Ovarian Cancer. <i>Acta Oncologica</i> , 2001, 40, 340-360.	0.8	84
106	Dose-dense cisplatin/paclitaxel. <i>European Journal of Cancer</i> , 2002, 38, 2005-2013.	1.3	34
107	Expression of Multidrug Resistance-Associated Markers, Their Relation to Quantitative Pathologic Tumour Characteristics and Prognosis in Advanced Ovarian Cancer. <i>Analytical Cellular Pathology</i> , 2002, 24, 17-23.	2.1	24
108	Interval debulking surgery in advanced epithelial ovarian cancer. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2002, 16, 573-583.	1.4	19
109	Chemotherapy for advanced epithelial ovarian carcinoma. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2002, 16, 553-571.	1.4	16
110	Copper-transporting P-type adenosine triphosphatase (ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma: Comparative analysis with expression of MDR1, MRP1, MRP2, LRP and BCRP. <i>International Journal of Cancer</i> , 2002, 101, 488-495.	2.3	132

#	ARTICLE	IF	CITATIONS
111	Relapsed, poor-prognosis ovarian cancer, individualized, interdisciplinary treatment approach, and quality of life: a case report. <i>Supportive Care in Cancer</i> , 2002, 10, 81-83.	1.0	1
112	Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer. <i>British Journal of Cancer</i> , 2002, 86, 19-25.	2.9	83
113	A dose-finding study of carboplatin+epirubicin+docetaxel in advanced epithelial ovarian cancer. <i>British Journal of Cancer</i> , 2002, 86, 1385-1390.	2.9	9
114	Multivariate Analysis of the Prognostic Significance of DNA-Ploidy and S-Phase Fraction in Ovarian Cancer Determined by Flow Cytometry Following Detection of Cytokeratin-Labeled Tumor Cells. <i>Gynecologic Oncology</i> , 2002, 84, 21-31.	0.6	17
115	A Population-Based Study of Patterns of Care for Ovarian Cancer: Who Is Seen by a Gynecologic Oncologist and Who Is Not?. <i>Gynecologic Oncology</i> , 2002, 84, 36-42.	0.6	193
116	The Western Australian Experience of the Use of en Bloc Resection of Ovarian Cancer with Concomitant Rectosigmoid Colectomy. <i>Gynecologic Oncology</i> , 2002, 84, 53-57.	0.6	57
117	The role of interval debulking surgery in ovarian cancer. <i>Current Oncology Reports</i> , 2003, 5, 473-481.	1.8	44
118	Sequential single agents as first-line chemotherapy for ovarian cancer: a strategy derived from the results of GOG-132. <i>International Journal of Gynecological Cancer</i> , 2003, 13, 156-162.	1.2	17
119	Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer. <i>European Journal of Surgical Oncology</i> , 2003, 29, 69-73.	0.5	115
120	Women's Experiences With Recurrent Ovarian Cancer. <i>Cancer Nursing</i> , 2003, 26, 10-17.	0.7	52
121	Ovarian and Fallopian Tube Cancers. , 0, , 377-393.		3
122	A Study of Pegylated Liposomal Doxorubicin in Platinum-Refractory Epithelial Ovarian Cancer. <i>Oncology</i> , 2004, 67, 183-186.	0.9	18
123	Remaining controversies in the upfront management of advanced ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2004, 14, 707-720.	1.2	18
124	Factors associated with cytoreducibility among women with ovarian carcinoma. <i>Gynecologic Oncology</i> , 2004, 95, 377-383.	0.6	51
126	Phase I clinical and pharmacologic study of a 2-weekly administration of cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. <i>Anti-Cancer Drugs</i> , 2005, 16, 1029-1036.	0.7	7
127	Brain metastases from epithelial ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2005, 15, 824-829.	1.2	29
128	Major hepatectomy and right hemicolectomy at the time of primary cytoreductive surgery for advanced ovarian cancer: report of a case. <i>International Journal of Gynecological Cancer</i> , 2005, 15, 1115-1119.	1.2	6
129	Apoptosis Rate and Objective Diagnosis of Drug Resistance of Ovarian Cancer Cell Lines. <i>Chinese-German Journal of Clinical Oncology</i> , 2005, 4, 304-308.	0.1	0



#	ARTICLE	IF	CITATIONS
130	Place de la chimiothérapie de première ligne dans le cancer de l'ovaire. Actualites Pharmaceutiques Hospitalieres, 2005, 1, 13-24.	0.1	0
132	Diagnosis and Management of Epithelial Ovarian Cancer. Obstetrics and Gynecology, 2006, 107, 1399-1410.	1.2	176
133	First-line gemcitabine and carboplatin in advanced ovarian carcinoma: a phase II study. BJOG: an International Journal of Obstetrics and Gynaecology, 2006, 113, 1388-1392.	1.1	7
134	Post-operative sequential high-dose chemotherapy with haematopoietic stem cell support as front-line treatment in advanced ovarian cancer: a phase II multicentre study. Bone Marrow Transplantation, 2006, 37, 651-659.	1.3	4
135	Ovarian cancer. Critical Reviews in Oncology/Hematology, 2006, 60, 159-179.	2.0	186
136	Viewing ovarian cancer as a "chronic disease": What exactly does this mean?. Gynecologic Oncology, 2006, 100, 229-230.	0.6	39
137	Cytoreductive Surgery for Gynecologic Malignancies: New Standards of Care. Surgical Oncology Clinics of North America, 2007, 16, 667-682.	0.6	7
138	The Role of Bowel Surgery with Cytoreduction for Epithelial Ovarian Cancer. Clinical Oncology, 2007, 19, 757-762.	0.6	15
139	Long-term survival in a randomized study of nonplatinum therapy versus platinum in advanced epithelial ovarian cancer. International Journal of Gynecological Cancer, 2007, 17, 986-992.	1.2	5
140	Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel: ANZGOG 02-01. Gynecologic Oncology, 2007, 104, 647-653.	0.6	21
141	Role of diaphragmatic surgery in 69 patients with ovarian carcinoma. International Journal of Gynecological Cancer, 2008, 18, 363-368.	1.2	35
142	Efficacy of taxane and platinum-based chemotherapy guided by extreme drug resistance assay in patients with epithelial ovarian cancer. Journal of Gynecologic Oncology, 2009, 20, 96.	1.0	25
143	Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer. British Journal of Cancer, 2009, 100, 707-712.	2.9	61
144	Treatment of Recurrent Platinum-Resistant Ovarian Cancer with Pegylated Liposomal Doxorubicin: An Evaluation of the Therapeutic Index with Special Emphasis on Cardiac Toxicity. Chemotherapy, 2009, 55, 391-398.	0.8	21
145	Weekly combination of topotecan and gemcitabine in early recurrent ovarian cancer patients: A French multicenter phase II study. Gynecologic Oncology, 2009, 115, 382-388.	0.6	6
146	Salvage therapy with topotecan in heavily pretreated ovarian cancer patients. Journal of Cancer Research and Clinical Oncology, 2009, 135, 815-821.	1.2	5
147	Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer. Journal of Clinical Oncology, 2009, 27, 5601-5606.	0.8	285
148	Ramirez's Abdominoplasty Technique Combined With Intraperitoneal Chemohyperthermia After Surgical Cytoreductive Procedures for the Treatment of Advanced Intraperitoneal Cancer in Patients With Ventral Hernia. Annals of Plastic Surgery, 2010, 64, 187-192.	0.5	3

#	ARTICLE	IF	CITATIONS
149	Sustained platelet-sparing effect of weekly low dose paclitaxel allows effective, tolerable delivery of extended dose dense weekly carboplatin in platinum resistant/refractory epithelial ovarian cancer. <i>BMC Cancer</i> , 2011, 11, 289.	1.1	11
150	Targeting Signaling Pathways in Epithelial Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2013, 14, 9536-9555.	1.8	51
151	Pegylated liposomal doxorubicin for platinum-resistant or refractory Malignant ovarian carcinoma (epithelial ovarian carcinoma, primary carcinoma of Fallopian tube and peritoneal carcinoma): A single-institutional experience. <i>Oncology Letters</i> , 2013, 5, 35-38.	0.8	4
152	Recent Advancements in Prognostic Factors of Epithelial Ovarian Carcinoma. <i>International Scholarly Research Notices</i> , 2014, 2014, 1-10.	0.9	25
153	Development of EGFR-Targeted Nanoemulsion for Imaging and Novel Platinum Therapy of Ovarian Cancer. <i>Pharmaceutical Research</i> , 2014, 31, 2490-2502.	1.7	36
154	Why have ovarian cancer mortality rates declined? Part II. Case-fatality. <i>Gynecologic Oncology</i> , 2015, 138, 750-756.	0.6	45
155	Oxaliplatin Is a Safe Alternative Option for Patients With Recurrent Gynecologic Cancers After Hypersensitivity Reaction to Carboplatin. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 42-48.	1.2	17
156	EGFR Targeted Theranostic Nanoemulsion for Image-Guided Ovarian Cancer Therapy. <i>Pharmaceutical Research</i> , 2015, 32, 2753-63.	1.7	24
157	Nanoscale Coordination Polymers Codeliver Carboplatin and Gemcitabine for Highly Effective Treatment of Platinum-Resistant Ovarian Cancer. <i>Molecular Pharmaceutics</i> , 2016, 13, 3665-3675.	2.3	37
158	A water-soluble polysaccharide from the roots of <i>Polygala tenuifolia</i> suppresses ovarian tumor growth and angiogenesis in vivo. <i>International Journal of Biological Macromolecules</i> , 2018, 107, 713-718.	3.6	25
159	Mathematical Modeling Predicts Response to Chemotherapy and Drug Combinations in Ovarian Cancer. <i>Cancer Research</i> , 2018, 78, 4036-4044.	0.4	31
160	Current Applications of Nanoemulsions in Cancer Therapeutics. <i>Nanomaterials</i> , 2019, 9, 821.	1.9	147
161	Is complete mesocolic excision or total mesorectal excision necessary during cytoreductive surgery in ovarian peritoneal carcinomatosis with colonic involvement?. <i>Acta Chirurgica Belgica</i> , 2023, 123, 124-131.	0.2	0
162	Cancer Metastasis: Biological and Clinical Aspects, <i>Gynaecological Cancer</i> . , 2000, , 381-420.		2
163	Prognostic factors in ovarian cancer. <i>Cancer Treatment and Research</i> , 1998, 95, 287-352.	0.2	20
164	Platinum Complexes. , 1997, , 93-112.		1
165	Ovaries and Fallopian Tubes. , 2008, , 1827-1855.		2
166	PRIMARY CHEMOTHERAPY IN EPITHELIAL OVARIAN CANCER. <i>Obstetrics and Gynecology Clinics of North America</i> , 1994, 21, 141-154.	0.7	4

#	ARTICLE	IF	CITATIONS
167	Long-Term Results in Patients with Advanced Epithelial Ovarian Carcinoma Treated with a Combination of Cisplatin, Doxorubicin, and Cyclophosphamide. American Journal of Clinical Oncology: Cancer Clinical Trials, 1997, 20, 522-526.	0.6	9
169	Survival of Advanced Stage High-Grade Serous Ovarian Cancer Patients in the Republic of Macedonia. Open Access Macedonian Journal of Medical Sciences, 2017, 5, 904-908.	0.1	8
170	Realistic goals of cancer therapy: effective and humane care. Cleveland Clinic Journal of Medicine, 1994, 61, 468-471.	0.6	4
171	Does Aquaporin-1 expression have clinical significance in serous epithelial ovarian cancer?. Journal of the Turkish German Gynecology Association, 2013, 14, 130-135.	0.2	6
172	Primary Chemotherapy for Advanced Epithelial Ovarian Cancer. , 2004, , 429-445.		0
173	ThÃ©rapeutiques du cancer de lâ€™ovaire. , 2011, , 531-576.		0
174	Combined Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for the Treatment of Advanced Ovarian Cancer. , 0, , .		0
175	Interval Debulking Surgery in Ovarian Cancer. Nepal Journal of Obstetrics and Gynaecology, 2011, 6, 3-6.	0.0	0
176	Der Beitrag zur verbesserten Behandlung epithelialer Ovariakarzinome: Aktuelle klinische Studien der kooperativen Arbeitsgruppe Ovariakarzinom (GOCA). , 1993, , 685-690.		0
177	The management of ovarian cancer. , 1997, , 85-89.		0
178	Ablative Chemotherapy in Solid Tumour Oncology, Technology in Search of an Application?. , 1997, , 123-130.		0
179	Gynecologic Tumors. , 1999, , 75-81.		0
181	Nanoemulsions for antitumor activity. , 2022, , 435-454.		0
182	Longitudinal single-cell RNA-seq analysis reveals stress-promoted chemoresistance in metastatic ovarian cancer. Science Advances, 2022, 8, eabm1831.	4.7	59